Advances in Smart Technologies for Structural Health Monitoring of Cable-stayed Bridges

This study deals with the general problem of developing smart technologies for vibration and impedance-based structural health monitoring (SHM) of cable-stayed bridges. The following approaches are implemented to achieve the objective. Firstly, vibration- and impedance-based SHM methods suitable for cable-stayed bridge are briefly outlined. Secondly, smart sensors are designed for vibration- and impedance-based SHM. Thirdly, the practicality of the smart sensor system is evaluated on a real cable-stayed bridge, Hwamyung Bridge in Korea. The system's performance is experimentally analyzed under various cable forces and weather conditions. Finally, the experimental modal parameters are identified by numerical modal analyses of the target bridge. Also, its structural parameters are estimated from the vibration-based structural identification using experimental modal parameters

Increased success probability in Hardy's nonlocality: Theory and demonstration

Depending on the way one measures, quantum nonlocality might manifest more visibly. Using basis transformations and interactions on a particle pair, Hardy logically argued that any local hidden variable theory leads to a paradox. Extended from the original work, we introduce a quantum nonlocal scheme for n-particle systems using two distinct approaches. First, a theoretical model is derived with analytical results for Hardy's nonlocality conditions and probability. Second, a quantum simulation using quantum circuits is constructed that matches very well to the analytical theory. When demonstrated on real quantum computers for n=3, we obtain reasonable results compared to theory. Even at macroscopic scales as n grows, the success probability asymptotes 15.6%, which is stronger than previous results.Comment: 4 pages, 4 figure

Disinfection performance of an ultraviolet lamp: a CFD investigation

Ultraviolet (UV)-based devices have shown their effectiveness on various germicidal purposes. To serve their design optimisation, the disinfection effectiveness of a vertically cylindrical UV lamp, whose wattage ranges from P = 30 − 100 W, is numerically investigated in this work. The UV radiation is solved by the Finite Volume Method together with the Discrete Ordinates model. Various results for the UV intensity and its bactericidal effects against several popular virus types, i.e., Corona-SARS, Herpes (type 2), and HIV, are reported and analysed in detail. Results show that the UV irradiance is greatly dependent on the lamp power. Additionally, it is indicated that the higher the lamp wattage employed, the larger the bactericidal rate is observed, resulting in the greater effectiveness of the UV disinfection process. Nevertheless, the wattage of P ≤ 100W is determined to be insufficient for an effective disinfection performance in a whole room; higher values of power must hence be considered in case intensive sterilization is required. Furthermore, the germicidal effect gets reduced with the viruses less sensitive to UV rays, e.g, the bactericidal rate against the HIV virus is only ∼8.98% at the surrounding walls

A facile synthesis and properties of bismuth vanadate (BiVO4) photocatalyst by hydrothermal method

In this study, BiVO4 photocatalysts were synthesized by hydrothermal method using Bi(NO3)3 5H2O and NH4VO3 as raw materials followed by calcination at different temperatures in the range from 350 °C to 600 °C. The as-synthesized BiVO4 samples were characterized by a number of physicochemical techniques including X-ray diffraction (XRD), Raman analysis, Scanning Electron Microscopy (SEM), and UV-Visible (UV-Vis) light diffuse reflectance spectrophotometry. The effect of temperatures calcination on structure, surface morphology, visible-light photocatalytic activity and light absorption performance of BiVO4 was discussed in details

Climate change and health in Southeast Asia – defining research priorities and the role of the Wellcome Trust Africa Asia Programmes

This article summarises a recent virtual meeting organised by the Oxford University Clinical Research Unit in Vietnam on the topic of climate change and health, bringing local partners, faculty and external collaborators together from across the Wellcome and Oxford networks. Attendees included invited local and global climate scientists, clinicians, modelers, epidemiologists and community engagement practitioners, with a view to setting priorities, identifying synergies and fostering collaborations to help define the regional climate and health research agenda. In this summary paper, we outline the major themes and topics that were identified and what will be needed to take forward this research for the next decade. We aim to take a broad, collaborative approach to including climate science in our current portfolio where it touches on infectious diseases now, and more broadly in our future research directions. We will focus on strengthening our research portfolio on climate-sensitive diseases, and supplement this with high quality data obtained from internal studies and external collaborations, obtained by multiple methods, ranging from traditional epidemiology to innovative technology and artificial intelligence and community-led research. Through timely agenda setting and involvement of local stakeholders, we aim to help support and shape research into global heating and health in the region

Climate change and health in Southeast Asia – defining research priorities and the role of the Wellcome Trust Africa Asia Programmes

This article summarises a recent virtual meeting organised by the Oxford University Clinical Research Unit in Vietnam on the topic of climate change and health, bringing local partners, faculty and external collaborators together from across the Wellcome and Oxford networks. Attendees included invited local and global climate scientists, clinicians, modelers, epidemiologists and community engagement practitioners, with a view to setting priorities, identifying synergies and fostering collaborations to help define the regional climate and health research agenda. In this summary paper, we outline the major themes and topics that were identified and what will be needed to take forward this research for the next decade. We aim to take a broad, collaborative approach to including climate science in our current portfolio where it touches on infectious diseases now, and more broadly in our future research directions. We will focus on strengthening our research portfolio on climate-sensitive diseases, and supplement this with high quality data obtained from internal studies and external collaborations, obtained by multiple methods, ranging from traditional epidemiology to innovative technology and artificial intelligence and community-led research. Through timely agenda setting and involvement of local stakeholders, we aim to help support and shape research into global heating and health in the region.</ns4:p

Climate change and health in Southeast Asia – defining research priorities and the role of the Wellcome Trust Africa Asia Programmes

This article summarises a recent virtual meeting organised by the Oxford University Clinical Research Unit in Vietnam on the topic of climate change and health, bringing local partners, faculty and external collaborators together from across the Wellcome and Oxford networks. Attendees included invited local and global climate scientists, clinicians, modelers, epidemiologists and community engagement practitioners, with a view to setting priorities, identifying synergies and fostering collaborations to help define the regional climate and health research agenda. In this summary paper, we outline the major themes and topics that were identified and what will be needed to take forward this research for the next decade. We aim to take a broad, collaborative approach to including climate science in our current portfolio where it touches on infectious diseases now, and more broadly in our future research directions. We will focus on strengthening our research portfolio on climate-sensitive diseases, and supplement this with high quality data obtained from internal studies and external collaborations, obtained by multiple methods, ranging from traditional epidemiology to innovative technology and artificial intelligence and community-led research. Through timely agenda setting and involvement of local stakeholders, we aim to help support and shape research into global heating and health in the region

An evaluation of purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever.

OBJECTIVES: The diagnosis of typhoid fever is a challenge. Aiming to develop a typhoid diagnostic we measured antibody responses against Salmonella Typhi (S. Typhi) protein antigens and the Vi polysaccharide in a cohort of Bangladeshi febrile patients. METHODS: IgM against 12 purified antigens and the Vi polysaccharide was measured by ELISA in plasma from patients with confirmed typhoid fever (n = 32), other confirmed infections (n = 17), and healthy controls (n = 40). ELISAs with the most specific antigens were performed on plasma from 243 patients with undiagnosed febrile disease. RESULTS: IgM against the S. Typhi protein antigens correlated with each other (rho > 0.8), but not against Vi (rho 0.85, respectively. Applying a dynamic cut-off to patients with undiagnosed febrile disease suggested that 34-58% had an IgM response indicative of typhoid. CONCLUSIONS: We evaluated the diagnostic potential of several S. Typhi antigens; our assays give good sensitivity and specificity, but require further assessment in differing patient populations

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke